Table 1 Clinical characteristics of the population divided by median DII. The table reports the clinical characteristics and the biochemical parameters of the population divided according to the median value of DII. N = 331 subjects displayed DII below the median (DII < median) and 332 subjects displayed DII over the median (DII > median)
From: High dietary inflammatory index associates with inflammatory proteins in plasma
Total sample (n = 663) | DII < median (n = 331) | DII > median (n = 332) | ||
|---|---|---|---|---|
Median (25th-75th percentiles) | Median (25th-75th percentiles) | Median (25th-75th percentiles) | p | |
Dietary Inflammatory Index | 1.60 (0.83–2.3) | 0.83 (0.29–1.18) | 2.30 (1.97–2.73) | - |
Age (years) | 56 (50–61) | 56 (50–61) | 55 (50–60) | 0.187 |
Female, n (%) | 447 (67.42) | 215 (64.95) | 232 (69.88) | 0.176 |
Smokers, n (%) | 126 (19) | 52 (15.71) | 74 (22.29) | 0.031 |
Physically active, n (%) | 295 (44.49) | 178 (53.78) | 117 (35.24) | < 0.001 |
Body Mass Index (kg/m^2) | 26.22 (23.81–28.81) | 25.84 (23.5-28.23) | 26.66 (24.23–29.18) | 0.006 |
Waist to Hips ratio | 0.8 (0-0.84) | 0.79 (0.71–0.83) | 0.8 (0-0.85) | 0.360 |
Systolic Blood Pressure (mmHg) | 130 (120–140) | 130 (120–140) | 130 (120–140) | 0.555 |
Diastolic Blood Pressure (mmHg) | 80 (80–90) | 80 (80–90) | 80 (80–90) | 0.822 |
Anti-hypertensive therapies, n (%) | 153 (23.08) | 75 (22.66) | 78 (23.49) | 0.799 |
Fasting glucose (mg/dL) | 88 (82–96) | 87 (81–96) | 89 (82–96) | 0.347 |
Glucose-lowering therapies, n (%) | 4 (0.6) | 2 (0.6) | 2 (0.6) | 0.998 |
Cholesterol (mg/dL), mean ± SD | 222.43 ± 38.55 | 224.07 ± 37.21 | 220.8 ± 39.84 | 0.275 |
HDL-C (mg/dL), mean ± SD | 54 (45–66) | 54 (45–67) | 54 (46–65) | 0.434 |
Triglycerides (mg/dL) | 91 (64–132) | 89 (63–127) | 92.5 (68-137.5) | 0.147 |
LDL-C (mg/dL) | 144.71 ± 35.76 | 146.48 ± 33.88 | 142.92 ± 37.53 | 0.202 |
Remnant cholesterol (mg/dL) | 18.2 (12.8–26.4) | 17.8 (12.6–25.4) | 24.64 ± 26.14 | 0.147 |
Apo A1 (mg/dL) | 149.95 ± 24.58 | 148.99 ± 23.77 | 149 (132–169) | 0.386 |
Apo B (mg/dL), mean ± SD | 112 (96–131) | 114.7 ± 24.96 | 112.22 ± 25.23 | 0.274 |
Apo A1/Apo B ratio | 0.75 (0.62–0.93) | 0.75 (0.63–0.95) | 0.74 (0.6–0.91) | 0.185 |
Lipid-lowering therapies, n (%) | 56 (8.45) | 27 (8.16) | 29 (8.73) | 0.789 |
CRP (mg/L) | 0.09 (0.05–0.16) | 0.08 (0.04–0.15) | 0.1 (0.06–0.17) | 0.004 |
Previous CVD events, n (%) | 0 (0) | 0 (0) | 0 (0) | . |
Antiplatelet therapies, n (%) | 13 (1.96) | 9 (2.72) | 4 (1.2) | 0.160 |